Search
for
Sort by
Research 30 of 1000+
- Efficacy of JAK 1/2 inhibition in the treatment of diffuse non-scarring alopecia due to systemic lupus erythematosus
- Selective Janus kinase 1 inhibition resolves inflammation and restores hair growth offering a viable treatment option for alopecia areata
- Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition
- Case Report: Reversal of Long-Standing Refractory Diffuse Non-Scarring Alopecia Due to Systemic Lupus Erythematosus Following Treatment With Tofacitinib
- Treatment of concomitant alopecia areata and systemic lupus erythematosus with ivarmacitinib: a case report and literature review
- Upadacitinib for the Treatment of Systemic Immune Co-Morbidity in One Case: Alopecia Areata, Vitiligo, Ankylosing Spondylitis, and Allergic Rhinitis-Asthma – Multifaceted Control
- Refractory alopecia in lupus treated with tofacitinib — a case-based review
- A Real-World Study of Steroid-Free Monotherapy with Tofacitinib in Severe and Therapy-Recalcitrant Alopecia Areata, Alopecia Totalis, and Alopecia Universalis Cases: A Retrospective Analysis
- Effective treatment of refractory alopecia areata in pediatric patients with oral abrocitinib
- Alopecia areata
- Exploring the efficacy of baricitinib in treating alopecia areata after failed Janus kinase inhibitor therapy
- Which is the ideal JAK inhibitor for alopecia areata – Baricitinib, tofacitinib, ritlecitinib or ifidancitinib - Revisiting the immunomechanisms of the JAK pathway
- Advances in the mechanism and new therapies of alopecia areata
- Multiomic Characterization of Treatment Response to JAK Inhibition in Patients with APECED
- Ruxolitinib: A novel molecule in the management of dermatological disorders
- Baricitinib for Alopecia Universalis Following Drug-Induced Hypersensitivity Syndrome/Drug Reaction with Eosinophilia and Systemic Symptoms
- Baricitinib: From Rheumatoid Arthritis to COVID‐19
- Successful treatment of alopecia universalis with abrocitinib: a case report
- Topical tofacitinib for patients with lichen planopilaris and/or frontal fibrosing alopecia
- 802 Molecular effect of brepocitinib in hidradenitis suppurativa (HS)
- Scarring hair follicle destruction is driven by the collapse of EGFR-protected JAK-STAT1-sensitive stem cell immune privilege
- Clinical evidence for JAK inhibition in alopecia areata: A comprehensive review
- Tofacitinib: The selected selective JAK inhibitor in paediatric dermatology
- Progressive alopecia areata during TNF-α inhibition with intralesional corticosteroid failure and subsequent improvement following JAK1 inhibition
- Emerging Topical and Systemic JAK Inhibitors in Dermatology
- Short-term Efficacy of Tofacitinib, a JAK Inhibitor, in IFIH1-related Aicardi-Goutières Syndrome
- Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib
- Inhibition of T-cell activity in alopecia areata: recent developments and new directions
- Systemic Tofacitinib Treatment in Pediatric Patients with Resistant Alopecia Areata
- 448 Combined therapeutic approach: Inhibition of MMP-9 and JAK Signaling Synergistically Prevents Depigmentation in Experimental Vitiligo